Osimertinib and Gefitinib in EGFR Inhibitor naive Advanced EGFR Mutant Lung Cancer
This research study is studying a combination of two drugs as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation.
The interventions involved in this study are:
- Osimertinib (Tagrisso)
- Gefitinib (Iressa)
A Phase 1/2 Study of osimertinib in combination or alternating with gefitinib in EGFR inhibitor naive advanced EGFR mutant lung cancer
- ClinicalTrials.gov Identifier: NCT03122717
- Protocol Number: 16-627
- Principal Investigator: Daniel Costa
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required